Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
MT

NASDAQ · MTVA

MetaVia Inc.

Healthcare · Biotechnology

$1.34

Up+$0.08 (+6.35%)

Updated Nov 5, 2026, 2:05 AM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
19.06M
P/E ratio
-1.19
Dividend yield
0.00%
52-week range
$0.97 – $4.31
Volume
148.27K
Avg. volume
316.98K

Price performance · MTVA

MTVA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 4, 2026

MTVA closed at $1.34 after 21 trading sessions, down 8.22% for the selected period.

Last close
$1.34
Period change
-8.22%
Period low
$1.12
Period high
$1.46
Daily close
View OHLC price history
MTVA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 4, 2026$1.26$1.45$1.26$1.34148.27K
Nov 3, 2026$1.17$1.26$1.17$1.2674.09K
Nov 2, 2026$1.19$1.2193$1.15$1.1754.14K
Oct 30, 2026$1.20$1.29$1.12$1.1274.06K
Oct 29, 2026$1.15$1.2495$1.12$1.1966.59K
Oct 28, 2026$1.17$1.1899$1.11$1.1493.96K
Oct 27, 2026$1.27$1.27$1.15$1.1569.55K
Oct 26, 2026$1.41$1.41$1.215$1.215137.36K
Oct 23, 2026$1.39$1.50$1.36$1.38101.04K
Oct 22, 2026$1.35$1.3948$1.35$1.3933.7K
Oct 21, 2026$1.29$1.37$1.29$1.3442.29K
Oct 20, 2026$1.26$1.32$1.20$1.2922.1K
Oct 19, 2026$1.29$1.32$1.225$1.2354.28K
Oct 16, 2026$1.38$1.43$1.26$1.2675.92K
Oct 15, 2026$1.35$1.44$1.325$1.3750.28K
Oct 14, 2026$1.40$1.4354$1.3504$1.3640.63K
Oct 13, 2026$1.52$1.52$1.415$1.4365.68K
Oct 12, 2026$1.43$1.5887$1.41$1.45137.24K
Oct 9, 2026$1.35$1.44$1.35$1.4151.05K
Oct 8, 2026$1.47$1.48$1.33$1.34113.98K
Oct 7, 2026$1.47$1.52$1.46$1.4630.84K

Latest MTVA news

The latest Smart Investors Daily articles mentioning MTVA.

Stock researchCompany · Overview

MTVA research

Overview

Company profile and research snapshot.

Company profile

MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
MTVA recent ratings
DateFirmRatingTarget
Jul 10, 2026HC Wainwright & Co.Buy—
May 18, 2026HC Wainwright & Co.Buy—
Mar 27, 2026HC Wainwright & Co.Buy—
Jan 6, 2026HC Wainwright & Co.Buy—
May 19, 2025Maxim GroupBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 28, 2026

MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from the Phase 1 clinical trial of DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors, has been accepted for an oral presentation at the Precision Liver Symposium 2026, taking place November 4, 2026, in Denver, Colorado.

Yahoo · Oct 13, 2026

MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the appointment of Sarah Browne, M.D., as Chief Medical Officer, effective October 12, 2026. Dr. Browne brings more than 20 years of experience spanning clinical development, regulatory science and clinical medicine, with particular expertise in liver and metabolic diseases, including metabolic dysfunction-associated steatohepatitis (MASH).

Yahoo · Sep 10, 2026

MTVA: Preclinical Findings Support DA-1726 Waist Circumference Reduction

By David Bautz, PhD NASDAQ: MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Preclinical Results Provide Insight into DA-1726 Mechanism of Waist Reduction On September 9, 2026, MetaVia, Inc. (NASDAQ: MTVA) announced the results of a preclinical study utilizing radioactively labeled DA-1726 to evaluate its tissue distribution following subcutaneous administration. The results showed that

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By